Branded Legacy, Inc. (OTC: BLEG), a leader in innovative addiction treatment and harm reduction solutions, announced that its subsidiary, BioLegacy Evaluative Group Inc., has initiated the engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This milestone advances scalable production of its single-use device designed for rapid, reliable therapeutic delivery, including its flagship inhaled naloxone program.
The development builds on a September 2025 provisional patent filing and the opening of a GMP-compliant facility in Vancouver. By moving toward mass production, Branded Legacy strengthens its capacity to address the opioid crisis through affordable, high-quality pharmaceutical solutions. The unitary mold approach is expected to reduce manufacturing complexity and costs, making the device more accessible for emergency use.
Branded Legacy’s inhaled naloxone program aims to provide a faster and more user-friendly alternative to injectable naloxone, which is critical during opioid overdoses. The company’s technology leverages air-driven propulsion for intranasal delivery, potentially improving drug absorption and onset of action. With the opioid epidemic claiming tens of thousands of lives annually, scalable production of such devices could significantly impact public health outcomes.
For further details on the press release, visit https://ibn.fm/Lgrhz. Branded Legacy continues to collaborate with leading institutions like McMaster University and Stanford University to drive transformative research. The company’s state-of-the-art GMP manufacturing facility in Vancouver positions it to deliver cutting-edge products for addiction treatment and harm reduction.
More information about Branded Legacy is available at https://BrandedLegacy.com. The company remains committed to addressing critical public health challenges through innovation and strategic partnerships.
